Medtronic Cardiovascular
The Harmony Transcatheter Pulmonary Valve (TPV) System is indicated for use in the management of pediatric and adult congenital heart disease patients with severe pulmonary regurgitation (i.e., severe pulmonary regurgitation as determined by echocardiography and/or pulmonary regurgitant fraction ≥ 30% as determined by cardiac magnetic resonance imaging) who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement as judged by the medical team.
Severe Pulmonary Valve Regurgitation
Certain imaging assessments can be non-Standard of Care
NA
Prospective, non-randomized, multi-center, post-market interventional clinical study
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 80 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Harmony TPV EMEA Post-Market Study |
Actual Study Start Date : | 2025-06-01 |
Estimated Primary Completion Date : | 2027-07-31 |
Estimated Study Completion Date : | 2032-12-31 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Rigshospitalet
Copenhagen, Denmark,
Not yet recruiting
Heart and Diabetes Center NRW
Bad Oeynhausen, Germany,
Not yet recruiting
German Heart Center of the Charité
Berlin, Germany, 12203
Not yet recruiting
German Heart Center Munich
Munich, Germany,
Not yet recruiting
Schneider Children's Medical Center Israel
Heels of a tip, Israel, 49202
Not yet recruiting
Hospital of Padua
Padova, Italy,
Not yet recruiting
Gregorio Marañón University General Hospital
Madrid, Spain, 28007
Not yet recruiting
Skåne University Hospital Lund
Lund, Sweden, 22185